We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




CSF Glucose Unaltered in Patients With Dementia

By LabMedica International staff writers
Posted on 14 Dec 2022
Print article
Image: The cobas 8000 modular analyzer series is a scalable module based serum work area (SWA) solution for a wide range of in vitro diagnostics testing of clinical chemistry & immunochemistry designed for high throughput laboratories (Photo courtesy of Roche Diagnostics)
Image: The cobas 8000 modular analyzer series is a scalable module based serum work area (SWA) solution for a wide range of in vitro diagnostics testing of clinical chemistry & immunochemistry designed for high throughput laboratories (Photo courtesy of Roche Diagnostics)

A plethora of the pathological processes of many dementia disorders begin several years before the clinical expression of the diseases, and for that reason it is important to discover new biomarkers and methods to detect these processes at an early stage.

Glucose is transported from the blood, through the blood brain barrier (BBB), and into the interstitial space, where it is made available for metabolism by astrocytes and neurons. Normally, there is a close relationship between cerebrospinal fluid (CSF) and plasma glucose concentrations, and the ratio ranges between 0.5 and 0.8, but the ratio may change in different pathological conditions.

Clinical Scientists at the Copenhagen University Hospital Rigshospitalet (Copenhagen, Denmark) and their colleagues collected CSF and plasma samples from patients referred for diagnostic evaluation. The samples were taken from 446 patients (Alzheimer’s Disease (AD) (n=320), vascular dementia (VaD) (n=64), frontotemporal dementia (FTD) (n=27) and dementia with Lewy bodies (DLB) (n=35)), and 130 healthy controls (HC) (healthy subjects (HS) (n=34), non-demented HS (n=96)).

CSF was collected in 5 mL polypropylene tubes, transported at room temperature, and analyzed on a Radiometer ABL instrument (Radiometer Medical ApS, Brønshøj, Denmark) within an hour after sampling. Plasma was collected in 2 mL Greiner bio-one VACUETTE tubes with Sodium Fluoride/Potassium Oxalate (Greiner, Kremsmünster, Austria), transported at room temperature, and analyzed on a COBAS 8000 instrument (Roche Diagnostics, Indianapolis, IN, USA) within three hours after sampling.

The investigators reported that no significant differences in CSF and plasma glucose levels between the dementia group and HC were found. Furthermore, no significant difference in the CSF/plasma glucose ratio was identified. When investigating CSF glucose, plasma glucose and the CSF/plasma glucose ratio for the different etiologies within the dementia group, no significant differences were found. In addition, no statistically significant differences were found in the relationship between age and CSF glucose, plasma glucose and the CSF/plasma glucose ratio.

The authors concluded that despite severe reductions in the glucose metabolism in the brain of patients with dementia disorders, CSF and plasma glucose levels and the CSF/plasma-glucose ratio do not reflect this hypometabolism, and do not differentiate between dementia of different etiologies. For that reason, it is unlikely that they will have diagnostic potential in a mixed memory clinic setting. The study was published on December 8. 2022 in the journal Clinical Biochemistry.

Related Links:
Copenhagen University Hospital Rigshospitalet
Radiometer Medical
Greiner
Roche Diagnostics

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Nutating Mixer
Enduro MiniMix
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.